✓ No loaded language, vague sourcing, or framing detected.
Colossal Biosciences is reportedly negotiating to raise new capital, which could elevate its valuation to between $20 billion and $30 billion. This would mark a significant increase from its prior valuation.
Our neutral summary
Colossal Biosciences is reportedly negotiating to raise new capital, which could elevate its valuation to between $20 billion and $30 billion. This would mark a significant increase from its prior valuation.
The reporting belongs to TechCrunch; we don't reproduce it.
No note attached
on this article.
Colossal Biosciences reportedly in talks to raise new capital at $20B–$30B valuation
Colossal Biosciences in discussions to raise capital at $20B–$30B valuation